# Dossier: CLOSTRA INC

## SBIR Award Details

**Award Title:** N/A

**Amount:** $179,998.78

**Award Date:** 2024-09-16

**Branch:** USAF

## AI-Generated Intelligence Summary

**Company Overview:**

ClostraBio Inc. is a biopharmaceutical company focused on developing novel therapies that address unmet needs in autoimmune and inflammatory diseases. Their primary mission is to harness the power of the microbiome to create targeted, disease-modifying treatments. ClostraBio aims to solve the problem of inflammation and immune dysregulation in autoimmune disorders by delivering beneficial microbial products directly to the gut, modulating the immune system from within. Their unique value proposition lies in their focus on \*Clostridia\* bacteria, a well-studied group of anaerobes known for their anti-inflammatory properties and their ability to induce immune tolerance.

**Technology Focus:**

* CBT-001:\*\* An orally administered, live biotherapeutic product (LBP) composed of a consortium of naturally occurring \*Clostridia\* strains. This product is designed to restore immune homeostasis by increasing the production of short-chain fatty acids (SCFAs) in the gut and promoting the differentiation of regulatory T cells (Tregs). Preclinical data suggests CBT-001 can reduce disease activity in mouse models of inflammatory bowel disease (IBD) and multiple sclerosis (MS).
* Proprietary Microbial Discovery Platform:\*\* This platform allows for the identification and characterization of novel \*Clostridia\* strains with specific immunomodulatory properties. The platform leverages advanced genomics, metabolomics, and bioinformatics to screen and select strains that produce desirable therapeutic effects.

**Recent Developments & Traction:**

* Phase 1b Clinical Trial (IBD):\*\* In 2023, ClostraBio initiated a Phase 1b clinical trial evaluating CBT-001 in patients with mild-to-moderate ulcerative colitis. Topline data from this trial is expected in late 2024 or early 2025.
* Series A Funding (2021):\*\* ClostraBio closed a $62 million Series A funding round led by Cobro Ventures and included participation from other investors. This funding is supporting the clinical development of CBT-001 and the advancement of their microbial discovery platform.
* Collaboration with Academic Institutions:\*\* The company has partnered with several leading academic institutions to conduct preclinical research and translational studies.

**Leadership & Team:**

* Dr. Ved V. Topkar (CEO):\*\* Experienced biotechnology executive with a background in drug development and commercialization. Previously held leadership positions at other biotech companies.
* John Young (Chief Medical Officer):\*\* Extensive experience in clinical development and regulatory affairs, with a focus on autoimmune and inflammatory diseases.

**Competitive Landscape:**

* Seres Therapeutics:\*\* Seres is developing microbiome-based therapeutics for various diseases, including IBD. ClostraBio differentiates itself by focusing specifically on \*Clostridia\* strains and their unique immunomodulatory properties, while Seres' approach is broader in terms of microbial composition.
* Finch Therapeutics:\*\* Finch develops microbiome-based therapies for recurrent \*C. difficile\* infection and IBD. ClostraBio's focus on a rationally defined consortium of \*Clostridia\* strains offers a more targeted approach compared to Finch's use of fecal microbiota transplantation (FMT) or their encapsulated donor-derived (CDD) therapies.

**Sources:**

1. [https://www.clostrabio.com/](https://www.clostrabio.com/)

2. [https://www.fiercebiotech.com/biotech/clostrabio-bags-62m-series-back-its-gut-bugs-autoimmune-disease](https://www.fiercebiotech.com/biotech/clostrabio-bags-62m-series-back-its-gut-bugs-autoimmune-disease)

3. [https://www.linkedin.com/company/clostrabio/](https://www.linkedin.com/company/clostrabio/)

4. [https://www.prnewswire.com/news-releases/clostrabio-launches-with-62-million-series-a-financing-to-develop-microbiome-based-therapies-for-autoimmune-and-inflammatory-diseases-301393282.html](https://www.prnewswire.com/news-releases/clostrabio-launches-with-62-million-series-a-financing-to-develop-microbiome-based-therapies-for-autoimmune-and-inflammatory-diseases-301393282.html)